ACYCLOVIR IN LOCALIZED HERPES ZOSTER IN IMMUNOCOMPRIMISED PATIENTS

阿昔洛韦治疗免疫功能低下患者的局限性带状疱疹

• 批准号: 3847272
• 负责人: RICHARD J WHITELY
• 金额: --
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3847272
• 关键词: acyclovir; antiviral agents; clinical trials; drug adverse effect; human subject; human therapy evaluation; immunodeficiency; microorganism disease chemotherapy; shingles; uracil analog

This is a randomized, double-blind, controlled trial to compare the efficacy of BV-ara-U vs acyclovir in the treatment of acute, localized, non-trigeminal zoster in immunocompromised patients. Patients will be evaluated for lesion stages, new lesion development, evidence of cutaneous or visceral dissemination, & evidence of intolerance or toxicity to the study drugs.

这是一项随机，双盲，对照试验，以比较 BV-ARA-U与Acyclovir在急性治疗，局部， 免疫功能低下的患者中的非三聚体带状疱疹。 患者会 评估病变阶段，新的病变发展，皮肤的证据 或内脏传播，以及对毒性不宽容或毒性的证据 研究药物。